The Basic Principles Of ABBV-744 in acute myeloid leukemia (AML)
In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment until finally illness progression or perhaps the participants are not able to tolerate the study drugs.- "Our study unveiled the important purpose with the KLF16/MYC regulatory axis in modula